Bastiaan Driehuys
The purpose of this study is to develop and evaluate the usefulness of MRI using 129Xe gas for regional assessment of pulmonary function. Specifically, three forms of 129Xe MRI contrast will be the investigators focus - 1) imaging of the 129Xe ventilation distribution, 2) imaging the alveolar microstructure via the 129Xe apparent diffusion coefficient (ADC), and 3) imaging 129Xe that dissolves in the pulmonary blood and tissues upon inhalation. Such imaging of 129Xe gas transfer is expected to be uniquely sensitive to pathologies affecting gas exchange (fibrosis, emphysema, pulmonary hypertension) and provide new insights regarding the normal resting heterogeneity of pulmonary gas exchange.
Non-invasive imaging of pulmonary function is expected to provide critical insights that are needed to spur progress in characterizing and treating chronic pulmonary diseases. The current primary diagnostic measure is pulmonary function testing (PFT), which was introduced in the mid-19th century, yet remains the standard of care today. PFTs have the advantage of being non-invasive and widely available, but suffer from poor sensitivity and high variability. Thus, PFTs are ineffective in assessing therapeutic response or disease progression on reasonable time scales, given the frequent heterogen…
Inclusion Criteria: Inclusion Criteria for Healthy Control Subjects 1. Subject has no diagnosed pulmonary conditions 2. Subject has not smoked in the previous 5 years. 3. Smoking history, if any, is less than or equal to 5 pack-years. Inclusion Criteria for Subjects with lung disease 1. Subject has a diagnosis of pulmonary dysfunction made by a physician 2. No acute worsening of pulmonary function in the past 30 days Exclusion Criteria: 1. Subject is less than 18 years old 2. MRI is contraindicated based on responses to MRI screening questionaire 3. Subject is pregnant or lactating 4. Re…
Hyperpolarized 129Xenon Gas will be administered in multiple doses in volumes that are tailored to the subject's total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
Arctuva estimate
Verify or correct the compensation shown for this listing.